-
Symbol
-
IKT on Nasdaq
-
Investment type
-
Equity / Common Stock, $0.001 par value
-
Latest Disclosed Shares Owned
-
13,018,965 shares
-
Security Ownership %
-
11%
Sands Capital Life Sciences Pulse Fund II, L.P. ownership in Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT)
13 Feb 2026 - Sands Capital Life Sciences Pulse Fund II, L.P. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 13,018,965 shares of Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT).
This represents 11% ownership of the company.
In their previous filing dated 13 Aug 2025, Sands Capital Life Sciences Pulse Fund II, L.P. had reported owning 10,950,000 shares, indicating an increase of +19%.
.